NCT03032107: A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

NCT03032107
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms. See trial for details.
https://ClinicalTrials.gov/show/NCT03032107

Comments are closed.

Up ↑